高级搜索

联合灌注预防浅表性膀胱肿瘤术后复发的临床观察

陈 忠, 李家贵, 叶章群, 杨为民, 张 旭, 曾晓勇

陈 忠, 李家贵, 叶章群, 杨为民, 张 旭, 曾晓勇. 联合灌注预防浅表性膀胱肿瘤术后复发的临床观察[J]. 肿瘤防治研究, 2005, 32(02): 108-109. DOI: 10.3971/j.issn.1000-8578.1193
引用本文: 陈 忠, 李家贵, 叶章群, 杨为民, 张 旭, 曾晓勇. 联合灌注预防浅表性膀胱肿瘤术后复发的临床观察[J]. 肿瘤防治研究, 2005, 32(02): 108-109. DOI: 10.3971/j.issn.1000-8578.1193
CHEN Zhong, LI Jia-gui, YE Zhang-qun, YANG Wei-min, ZHANG Xu, ZENG Xiao-yong. Clinical Study of Sequential Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Surgical Management[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 108-109. DOI: 10.3971/j.issn.1000-8578.1193
Citation: CHEN Zhong, LI Jia-gui, YE Zhang-qun, YANG Wei-min, ZHANG Xu, ZENG Xiao-yong. Clinical Study of Sequential Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Surgical Management[J]. Cancer Research on Prevention and Treatment, 2005, 32(02): 108-109. DOI: 10.3971/j.issn.1000-8578.1193

联合灌注预防浅表性膀胱肿瘤术后复发的临床观察

详细信息
    通讯作者:

    陈 忠

  • 中图分类号: R737. 14 ;R979.1

Clinical Study of Sequential Intravesical Instillations for the Prevention of Bladder Cancer Recurrence after Surgical Management

More Information
    Corresponding author:

    CHEN Zhong

  • 摘要: 目的 了解联合膀胱腔内灌注化疗方案对预防浅表性膀胱癌复发的疗效,探讨一种理想的膀胱腔内灌注方法。方法 将45例(男性34例,女性11例)年龄在31~80岁(平均56.1岁)浅表性膀胱癌患者随机分为A、B和C3组。A组接受单次表阿霉素灌注作为对照,B、C组接受不同的羟基喜树碱和丝裂霉素C序贯膀胱腔内灌注联合用药方案。结果 A、B、C组平均随访时间分别为26.6月、36.73月、24.31月,复发率分别为54.5%(6/11)、27.7%(5/18)、6.25%(1/16)。结论 羟基喜树碱和丝裂霉素C合理地联合应用能取得较好疗效。

     

    Abstract: Objective  To determine the effect of sequential int ravesical instillation to prevent superficial bladder cancer recurrence and seek ideal methods of int ravesical instillation. Methods  Four-five patients (34 men, 11 women) with superficial bladder cancer, mean age of 56. 1 years ( range 31~80), were randomly divided into three groups. A group received a single int ravesical instillation of epirubicin as control, B group and C group received different sequential int ravesical instillation of hydroxycamptothecine ( HCPT) and mitomycin Cn (MMC) individually. Results  The mean follow-up are 26. 36 months, 36. 73 months and 24. 31 months for A, B, C groups. The recur rates are 54. 5 % ( 6/ 11 ), 27. 7 % ( 5/ 18 ), 6. 25 %(1/ 16) individually. Conclusion  The result s showed that sequential int ravesical with HCPT and MMC in reason maybe have better effect s than a single int ravesical instillation of epirubicin.

     

计量
  • 文章访问数:  2064
  • HTML全文浏览量:  51
  • PDF下载量:  904
  • 被引次数: 0
出版历程
  • 收稿日期:  2004-01-05
  • 修回日期:  2004-05-12
  • 刊出日期:  2005-02-04

目录

    /

    返回文章
    返回
    x 关闭 永久关闭